World Journal of Dentistry

Register      Login

VOLUME 12 , ISSUE 4 ( July-August, 2021 ) > List of Articles

EDITORIAL

Therapeutic Benefits of Caffeine in Oral Submucous Fibrosis

Namrata Sengupta, Sachin C Sarode, Gargi S Sarode, Urmi Ghone, Shankargouda Patil

Citation Information : Sengupta N, Sarode SC, Sarode GS, Ghone U, Patil S. Therapeutic Benefits of Caffeine in Oral Submucous Fibrosis. World J Dent 2021; 12 (4):263-264.

DOI: 10.5005/jp-journals-10015-1835

License: CC BY-NC 4.0

Published Online: 15-07-2021

Copyright Statement:  Copyright © 2021; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract


PDF Share
  1. Shih YH, Wang TH, Shieh TM, et al. Oral submucous fibrosis: a review on etiopathogenesis, diagnosis, and therapy. Int J Mol Sci 2019;20(12):2940. DOI: 10.3390/ijms20122940.
  2. Ahmad MS, Ali SA, Ali AS, et al. Epidemiological and etiological study of oral submucous fibrosis among gutkha chewers of Patna, Bihar, India. J Indian Soc Pedod Prev Dent 2006;24(2):84–89. DOI: 10.4103/0970-4388.26022.
  3. Aziz SR. Oral submucous fibrosis: case report and review of diagnosis and treatment. J Oral Maxillofac Surg 2008;66(11):2386–2389. DOI: 10.1016/j.joms.2008.06.064.
  4. Arakeri G, Brennan PA. Oral submucous fibrosis: an overview of the aetiology, pathogenesis, classification, and principles of management. Br J Oral Maxillofac Surg 2013;51(7):587–593. DOI: 10.1016/j.bjoms.2012.08.014.
  5. Arakeri G, Rai KK, Hunasgi S, et al. Oral submucous fibrosis: an update on current theories of pathogenesis. J Oral Pathol Med 2017;46(6):406–412. DOI: 10.1111/jop.12581.
  6. Liu CM, Liao YW, Hsieh PL, et al. miR-1246 as a therapeutic target in oral submucosa fibrosis pathogenesis. J Formos Med Assoc 2019;118(7):1093–1098. DOI: 10.1016/j.jfma.2019.02.014.
  7. Angadi PV, Rao SS. Areca nut in pathogenesis of oral submucous fibrosis: revisited. Oral Maxillofac Surg 2011;15(1):1–9. DOI: 10.1007/s10006-010-0219-8.
  8. Prabhu RV, Prabhu V, Chatra L, et al. Areca nut and its role in oral submucous fibrosis. J Clin Exp Dent 2014;6(5):e569–e575. DOI: 10.4317/jced.51318.
  9. Shen YW, Shih YH, Fuh LJ, et al. Oral submucous fibrosis: a review on biomarkers, pathogenic mechanisms, and treatments. Int J Mol Sci 2020;21(19):7231. DOI: 10.3390/ijms21197231.
  10. Peng Q, Li H, Chen J, et al. Oral submucous fibrosis in Asian countries. J Oral Pathol Med 2020;49(4):294–304. DOI: 10.1111/jop.12924.
  11. James L, Shetty A, Rishi D, et al. Management of oral submucous fibrosis with injection of hyaluronidase and dexamethasone in grade III oral submucous fibrosis: a retrospective study. J Int Oral Health 2015;7(8):82–85.
  12. Rajesh Kashyap R, Shanker Kashyap R. Herbal derivatives in the management of mouth opening in oral submucous fibrosis-a network meta-analysis. Oral Dis 2020. DOI: 10.1111/odi.13544.
  13. Modi AA, Feld JJ, Park Y, et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology 2010;51(1):201–209. DOI: 10.1002/hep.23279.
  14. Tatler AL, Barnes J, Habgood A, et al. Caffeine inhibits TGFβ activation in epithelial cells, interrupts fibroblast responses to TGFβ, and reduces established fibrosis in ex vivo precision-cut lung slices. Thorax 2016;71(6):565–567. DOI: 10.1136/thoraxjnl-2015-208215.
  15. Donejko M, Przylipiak A, Rysiak E, et al. Influence of caffeine and hyaluronic acid on collagen biosynthesis in human skin fibroblasts. Drug Des Devel Ther 2014;8:1923–1928. DOI: 10.2147/DDDT.S69791.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.